TruDx LABORATORY
MOLECULAR DIAGNOSTICS

Urinary Tract Infectious Pathogen Panel

Acct: Mountain Crest Medical
Address 1
Address 2
Phone

Ordering Provider:

Name: Demo Patient
DOB: 7/5/2000 ·**Age:** 23 · **Sex:** M
Phone: (xxx) xxx-xxxx
ID#: M123456789

Test Type: Molecular PCR

Specimen Type: Urine **Acc. Number:** 123456789 **Collected:** 7/4/2023 **Received:** 7/5/2023

Test Status: Finalized **Finalization Date:** 7/5/2023

UTI PATHOGENS	Detected	Range Copies/µL
Acinetobacter baumannii		
Actinobaculum schaalii	☑	High >100,00 copies
Aerococcus urinae		
Candida albicans		
Candida others (glabrata, tropicalis, parapsilosis, krusei)		
Citrobacter freundii		
Citrobacter koseri	☑	Medium 50,000-100,00 Copies
Corynebacterium urealyticum		
Enterobacter cloacae complex		
Enterococcus faecalis		
Enterococcus faecium		
Escherichia coli		
Klebsiella (Enterobacter) aerogenes		
Klebsiella oxytoca		

UTI PATHOGENS	Detected	Range Copies/µL
Klebsiella pneumoniae		
Morganella morganii	☑	Low 5,000-50,000 Copies
Pantoea agglomerans		
Proteus mirabilis		
Proteus vulgaris		
Providencia stuartii		
Pseudomonas aeruginosa		
Serratia marcescens		
Staphylococcus aureus		
Staphylococcus epidermidis		
Staphylococcus saprophyticus		
Streptococcus agalactiae		
Streptococcus anginosus		

Range	High	Medium	Low
Copies/ µL	>100,000 Copies	10,000-100,000 Copies	10-10,000 Copies

Antibiotic Resistance Genes	Detected
Oxacillinase-48 (OXA-48)	
Klebsiella pnuemoniae cabapenemase (KPC)	☑
Verona Inegron-encoded Metallo- Beta- Lactamase (VIM)	
New Delhi Metallo-beta-lactamase (NDM)	
Imipenemase (IMP)	
Vancomycin resistance A (VanA)	
Vancomycin resistance B (VanB)	
Cefotaximase Extended Spectrum Beta-Lactamase (CTX-M)	

Powered by the OneChoice® Report from Arkstone Medical Group

End Of Report

Lab Director: Dr. XYZ
Phone: (xxx) xxx-xxxx

TruDx LLC.
480 N Sam Houston Pkwy East, Suite 382
Houston TX 75080

CLIA Certified
COLA ACCREDITED LAB

Disclosures

Processing and detection methodology: The infectious disease and antibiotic resistance panel is tested using Real-Time PCR technology to detect genes of listed pathogens and antibiotic resistance markers. The BioRad C1000 Touch Real-Time PCR System detects the presence of genes associated with the listed pathogens and antibiotic resistance targets by amplification of the genetic material. The panels test for the following pathogens and antibiotic resistance: Acinetobacter baumannii, Actinobaculum schaalii, Aerococcus urinae, Candida albicans, Candida pool (glabrata, tropicalis, parapsilosis, krusei), Citrobacter freundii, Citrobacter koseri, Corynebacterium urealyticum, Enterobacter cloacae complex, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella (Enterobacter) aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Pantoea agglomerans, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus anginosus, Klebsiella pnuemoniae cabapenemase (KPC),Verona Inegron-encoded Metallo- Beta-Lactamase (VIM), New Delhi Metallo-beta-lactamase (NDM),Imipenemase (IMP), Oxacillinase-48 (OXA-48), VanA, VanB, CTX-M.

Disclaimer: TruDx Laboratories is regulated by COLA and possess a Certificate of Accreditation to perform high-complexity molecular testing. TruDx validated this test and determined its performance characteristics in conjunction with SeeGene. The FDA has not cleared or approved this test panel. This test panel is for clinical purposes and not considered for research or as investigational. This information is for consideration only and must be applied, if at all, only on the basis of the independent judgment of the authorized medical provider receiving this report given the provider's training and experience as well as the patient's entire clinical and diagnostic presentation including, but not limited to, clinical condition, medical history, allergies, comorbidities, weight, diagnostic test results, etc., which may impact whether any recommendation provided herein is appropriate. The supplied guidance is limited to the data detected by the selected test panel, according to the methodology set forth herein, and otherwise provided in the test requisition form. Whether a given course of treatment applies to a given patient must be determined solely by the provider treating the patient. If the provider seeks additional information regarding the information in this report, the provider can use the contact information provided at onboarding.

Limitations: This test solely detects genes specified in the selected test panels which includes both microorganisms and antibiotic resistance markers. The presence of a pathogen indicated by the selected panel does not necessarily mean the pathogen is the cause of an infection or that the pathogen is alive, however, the pathogens are known to be associated with infection and should be clinically correlated. Testing involving Antibiotic resistance marker targets are not tied to a particular explicitly, and can be detected in microorganisms not specifically tested for by the panel as well as those tested for by the